CHRS vs GSK · rev $26.6M vs P/E 13, $103.31B cap
Coherus BioSciences Inc (CHRS) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
GSK does not have a complete income-statement cache yet.
CHRS currently screens at market cap $223.7M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the CHRS and GSK stock pages for the full models.
Not investment advice.